4.7 Meeting Abstract

Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 15, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.2021.39.15_suppl.9508

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available